INFIQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INFIQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Infinity Pharmaceuticals's gross profit for the three months ended in Jun. 2023 was $0.23 Mil. Infinity Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Jun. 2023 was $1.02 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Infinity Pharmaceuticals's gross profit for the three months ended in Jun. 2023 was $0.23 Mil. Infinity Pharmaceuticals's Revenue for the three months ended in Jun. 2023 was $0.58 Mil. Therefore, Infinity Pharmaceuticals's Gross Margin % for the quarter that ended in Jun. 2023 was 39.62%.
Infinity Pharmaceuticals had a gross margin of 39.62% for the quarter that ended in Jun. 2023 => Competition eroding margins
During the past 13 years, the highest Gross Margin % of Infinity Pharmaceuticals was 99.69%. The lowest was -139.69%. And the median was 39.72%.
The historical data trend for Infinity Pharmaceuticals's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Infinity Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Gross Profit | Get a 7-Day Free Trial | 22.08 | -4.26 | 0.68 | 0.74 | 1.03 |
Infinity Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Gross Profit | Get a 7-Day Free Trial | 0.27 | 0.28 | 0.22 | 0.29 | 0.23 |
For the Biotechnology subindustry, Infinity Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Infinity Pharmaceuticals's Gross Profit distribution charts can be found below:
* The bar in red indicates where Infinity Pharmaceuticals's Gross Profit falls into.
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Infinity Pharmaceuticals's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as
Gross Profit (A: Dec. 2022 ) | = | Revenue | - | Cost of Goods Sold |
= | 2.593 | - | 1.563 | |
= | 1.03 |
Infinity Pharmaceuticals's Gross Profit for the quarter that ended in Jun. 2023 is calculated as
Gross Profit (Q: Jun. 2023 ) | = | Revenue | - | Cost of Goods Sold |
= | 0.583 | - | 0.352 | |
= | 0.23 |
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.02 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
Infinity Pharmaceuticals's Gross Margin % for the quarter that ended in Jun. 2023 is calculated as
Gross Margin % (Q: Jun. 2023 ) | = | Gross Profit (Q: Jun. 2023 ) | / | Revenue (Q: Jun. 2023 ) |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | 0.23 | / | 0.583 | |
= | 39.62 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Infinity Pharmaceuticals (OTCPK:INFIQ) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Infinity Pharmaceuticals had a gross margin of 39.62% for the quarter that ended in Jun. 2023 => Competition eroding margins
Thank you for viewing the detailed overview of Infinity Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Adelene Q Perkins | director, officer: President & CEO | C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Stephane Peluso | officer: Chief Scientific Officer | 1100 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138 |
Brian Schwartz | director | C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803 |
Robert Jr. Ilaria | officer: Chief Medical Officer | 1100 MASSACHUSETTS AVENUE, 4TH FLOOR, CAMBRIDGE MA 02138 |
Biotechnology Value Fund L P | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Bvf Gp Holdings Llc | 10 percent owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Bvf Ii Gp Llc | other: See Explanation of Responses | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Bvf I Gp Llc | other: See Explanation of Responses | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Richard Gaynor | director | C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139 |
Jeffery Kutok | officer: Chief Scientific Officer | 784 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Samuel Agresta | officer: Chief Medical Officer | 784 MEMORIAL DR., CAMBRIDGE MA 02139 |
David W Beier | director | AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
Lawrence E Bloch | officer: EVP, CFO & CBO | |
Michael Kauffman | director | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459 |
Michael C Venuti | director |
From GuruFocus
By Marketwired • 08-31-2023
By PRNewswire • 08-26-2023
By Marketwired • 09-10-2023
By Marketwired • 09-01-2023
By Marketwired • 08-28-2023
By PRNewswire • 09-09-2023
By Marketwired • 10-11-2023
By PRNewswire • 09-16-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.